MYNZ Share Price Performance
Recent MYNZ News & Updates
No updates
Mainz Biomed N.V. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -6.29
- Gross Margin
- 64.31%
- Net Profit Margin
- -2,421.80%
- Debt/Equity Ratio
- 35.1%
Mainz Biomed N.V. Competitors
About MYNZ
- Founded
- 2008
- Employees
- 23
- CEO
- WebsiteView website
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
German Market Performance
- 7 Days: -0.2%
- 3 Months: -1.3%
- 1 Year: 19.8%
- Year to Date: 4.7%
In the last week, the market has stayed flat, however the Communication Services sector stood out, gaining 13%. As for the longer term, the market has risen 20% in the past 12 months. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading